急性治疗的 HIV 患者中 Ad26 和 MVA 疫苗的安全性和免疫原性，以及对中断抗逆转录病毒治疗后病毒反弹的影响。
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
机构信息
SEARCH, Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
Janssen Vaccines, Bern, Switzerland.
出版信息
Nat Med. 2020 Apr;26(4):498-501. doi: 10.1038/s41591-020-0774-y. Epub 2020 Mar 23.
We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. The vaccine was safe and generated robust immune responses, but delayed time to viral rebound compared to that in placebo recipients by only several days and did not lead to viremic control after treatment interruption (clinical trial NCT02919306).
我们在 26 名急性人类免疫缺陷病毒感染期间开始接受抗逆转录病毒治疗的个体中，给予了含有嵌合 HIV-1 抗原的 Ad26、改良安卡拉痘苗载体或安慰剂，这是一项探索性研究，旨在确定治疗中断后病毒血症控制的安全性和持续时间。该疫苗是安全的，并产生了强烈的免疫反应，但与安慰剂组相比，仅延迟了几天病毒反弹的时间，并且在治疗中断后并没有导致病毒血症的控制（临床试验 NCT02919306）。
Zotero 插件